Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Jagiellonian University |
---|---|
Information provided by: | Jagiellonian University |
ClinicalTrials.gov Identifier: | NCT00576940 |
The aim of the study was to assess the clinical effect of immunomodulating enteral nutrition in patients undergoing resection for gastrointestinal cancer. 196 subjects were randomly assigned into two study groups: standard and immunostimulating. The study failed to demonstrate any clear advantage of routine postoperative immunonutrition in patients undergoing elective upper gastrointestinal surgery
Condition | Intervention | Phase |
---|---|---|
Gastric Cancer Pancreatic Cancer |
Drug: Reconvan Drug: Peptisorb |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial |
Enrollment: | 196 |
Study Start Date: | June 2004 |
Study Completion Date: | September 2007 |
Arms | Assigned Interventions |
---|---|
IMEN: 1: Experimental
Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
|
Drug: Reconvan
isocaloric, immunomodulating entral diet
|
SEN: Active Comparator
postoperative enteral nutrition - standard oligopeptic diet
|
Drug: Peptisorb
isocaloric, isopeptic standard diet
|
Background&Aim: The administration of immunomodulating enteral diets during postoperative period in patients after major gastrointestinal surgery is intended to reduce the number of postoperative complications and to shorten the hospital stay. The aim of the study was to assess the clinical effect of enteral immunostimulatory nutrition in surgical patients.
Material and Methods: 196 patients undergoing resection for pancreatic and gastric cancer were randomized in double-blind manner to receive early postoperative enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids) or oligopeptic control (SEN group) between June 2004 and September 2007. Enteral nutrition was started 6 hours after surgery and continued for 7 days, up to target volume of 100 ml/h. All malnourished patients requiring preoperative nutritional therapy were excluded for the study and treated preoperatively. Outcome measures were: number and type of complications, length of hospital stay, mortality, treatment tolerance, liver and kidney function.
Results: One hundred eighty-three patients (91 in SEN, 92 in IMEN group, 69 F, 114 M, mean age 61.2) of 196 initially enrolled were analyzed. There were 2 deaths in both groups. Median postoperative hospital stay was 12.4 days (SD 5.9) in SEN group and 12.9 days (SD 8.0) in IMEN group (p=0.42). Complications were observed in 21 patients (23.1%) in SEN and 23 (25.2%) in IMEN group (p>0.05). 4 (4.4%) patients in SEN group and 4 (4.4%) in IMEN had surgical complications (p>0.05). There were no differences in liver and kidney function, visceral protein concentration and treatment tolerance.
Conclusion: Clinical and laboratory parameters show no benefit of immunomodulating enteral nutrition over standard enteral nutrition in patients after major gastrointestinal surgery as far as complications, hospital stay, mortality and treatment tolerance and safety are considered.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Jagiellonian University ( 1st Department of Surgery ) |
Study ID Numbers: | 1st Dept Surg Enteral, Immunoenteral |
Study First Received: | December 18, 2007 |
Last Updated: | December 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00576940 |
Health Authority: | Poland: Ministry of Health |
enteral nutrition, immunomodulating nutrition |
Stomach Diseases Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Pancreatic Neoplasms Stomach Neoplasms |
Endocrine System Diseases Pancreatic Diseases Gastrointestinal Neoplasms Stomach cancer Endocrinopathy Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site |